Imperial College London

ProfessorPhilippeSteg

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.steg

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Summary

Dr Steg has been a Professor of Cardiology at Université Paris - Diderot since 1994. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK. He works as an interventional cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France. He is also Director of the “Clinical Research in Atherothrombosis” Research Team, which belongs to INSERM U-1148, Paris and a co-coordinator of the Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling) affiliated with INSERM, Université Paris-Diderot and Assistance Publique – Hôpitaux de Paris. He is chair of the FACT (French Alliance for Cardiovascular clinical Trials) academic research network.

Dr Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.

Dr Steg led the TAO and EUROMAX trials and is currently chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Dr Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the Journal of the American College of Cardiology. Finally, Dr Steg was co-chair of the task force in charge of the 2012 ESC Guidelines for management of ST-segment elevation myocardial infarction.

E-mail: gabriel.steg@bch.aph.fr

Publications

Journals

Furtado RHM, Nicolau JC, Magnani G, et al., 2020, Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54., Eur Heart J, Vol:41, Pages:1625-1632

ten Berg JM, Steg PG, Bhatt DL, et al., 2020, Comparison of the Effect of Age (< 75 Versus >= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial), American Journal of Cardiology, Vol:125, ISSN:0002-9149, Pages:735-743

Vidal-Petiot E, Greenlaw N, Kalra PR, et al., 2020, Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry, Journal of Clinical Medicine, Vol:9

Sinnaeve PR, Schwartz GG, Wojdyla DM, et al., 2019, Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis., Eur Heart J

Akerblom A, Wojdyla D, Steg PG, et al., 2019, Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial, Journal of Thrombosis and Thrombolysis, Vol:48, ISSN:0929-5305, Pages:563-569

More Publications